Evidence map›Paper›PMID 25350564›Full record

ArticlePloS one2014

Glucolipotoxicity impairs ceramide flow from the endoplasmic reticulum to the Golgi apparatus in INS-1 β-cells.

Enida Gjoni, Loredana Brioschi, Alessandra Cinque, Nicolas Coant, M Nurul Islam, Carl K-Y Ng, Claudia Verderio, Christophe Magnan, Laura Riboni, Paola Viani and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Contribution of specific ceramides to obesity-associated metabolic diseases.Cellular and molecular life sciences : CMLS · 2022
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Protein Kinases Signaling in Pancreatic Beta-cells Death and Type 2 Diabetes.Advances in experimental medicine and biology · 2021
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Enida GjoniDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
Loredana BrioschiDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
Alessandra CinqueDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
Nicolas CoantUnité Biologie Fonctionnelle et Adaptative -UMR CNRS 8251, Université PARIS- DIDEROT (7), Paris, France.
M Nurul IslamSchool of Biology and Environmental Science and UCD Earth Institute, University College Dublin, Belfield, Ireland.
Carl K-Y NgSchool of Biology and Environmental Science and UCD Earth Institute, University College Dublin, Belfield, Ireland.
Claudia VerderioDepartment of Medical Biotechnology and Translational Medicine, CNR Institute of Neuroscience, Universita' di Milano, Milano, Italy.
Christophe MagnanUnité Biologie Fonctionnelle et Adaptative -UMR CNRS 8251, Université PARIS- DIDEROT (7), Paris, France.
Laura RiboniDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
Paola VianiDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
Hervé Le StunffUnité Biologie Fonctionnelle et Adaptative -UMR CNRS 8251, Université PARIS- DIDEROT (7), Paris, France.
Paola GiussaniDepartment of Medical Biotechnology and Translational Medicine, Università di Milano, LITA Segrate, Milano, Italy.
University College Dublin · IEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that glucolipotoxicity, arising from the combined actions of elevated glucose and free fatty acid levels, acts as a key pathogenic component in type II diabetes, contributing to β-cell dysfunction and death. Endoplasmic reticulum (ER) stress is among the molecular pathways and regulators involved in these negative effects, and ceramide accumulation due to glucolipotoxicity can be associated with the induction of ER stress. Increased levels of ceramide in ER may be due to enhanced ceramide biosynthesis and/or decreased ceramide utilization. Here, we studied the effect of glucolipotoxic conditions on ceramide traffic in INS-1 cells in order to gain insights into the molecular mechanism(s) of glucolipotoxicity. We showed that glucolipotoxicity inhibited ceramide utilization for complex sphingolipid biosynthesis, thereby reducing the flow of ceramide from the ER to Golgi. Glucolipotoxicity impaired both vesicular- and CERT-mediated ceramide transport through (1) the decreasing of phospho-Akt levels which in turn possibly inhibits vesicular traffic, and (2) the reducing of the amount of active CERT mainly due to a lower protein levels and increased protein phosphorylation to prevent its localization to the Golgi. In conclusion, our findings provide evidence that glucolipotoxicity-induced ceramide overload in the ER, arising from a defect in ceramide trafficking may be a mechanism that contributes to dysfunction and/or death of β-cells exposed to glucolipotoxicity.

Indexed as

AnimalsCell LineCell SurvivalCeramidesDiabetes MellitusEndoplasmic ReticulumEndoplasmic Reticulum StressGlucoseGolgi ApparatusInsulinomaInsulin-Secreting CellsPalmitic AcidPhosphorylationRatsRNA InterferenceSphingomyelinsCeramidesGlucosePalmitic AcidSphingomyelinsSphingosine

Identifiers

PMID25350564
PMCPMC4211692
OpenAlexW2048749392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.